EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A study of the efficacy and safety of plaque psoriasis treatment by TNF‐α and IL‐17A inhibitor biologics in patients who received the inactivated SARS‐CoV‐2 vaccine

Shuhong Ye iD, Hong Sun, Zining Xu, Bingyang Xu, Na Wu, Jiawen Wu

Immunity, Inflammation and Disease · 2023

DOI: 10.1002/iid3.938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2023. Verfasst von Shuhong Ye und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'An, Shaanxi, China. Hauptthemen laut MEDLINE: Biological Products, COVID-19, Psoriasis. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vaccination is an important method for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) transmission. There is currently a lack of real‐world clinical data regarding the safety and efficacy of coronavirus disease 2019 (COVID‐19) vaccines with respect to plaque psoriasis treatment involving tumor necrosis factor‐α (TNF‐α) and interleukin‐17A (IL‐17A) inhibitors.

Methods

We longitudinally analyzed 152 patients with plaque psoriasis, 86 of whom received two doses of inactivated COVID‐19 vaccine (either BBIBP‐CorV or CoronaVac). Comparisons were made between patients undergoing treatment with biologics (TNF‐ α inhibitors or IL‐17A inhibitors) or acitretin. Routine blood tests were used to assess safety; the psoriasis area and severity index (PASI) and dermatology life quality index (DLQI) were used to assess efficacy.

Results

After inactivated COVID‐19 vaccination, biologics retained considerable advantages in terms of improving skin lesions (measured by PASI) and quality of life (measured by DLQI), compared with conventional treatment ( p < 0.05 and p < 0.01, respectively). Routine blood tests and hepatorenal function analyses suggested that inactivated SARS‐CoV‐2 vaccines did not alter the safety of biologics treatment ( p > 0.05).

Conclusions

Inactivated SARS‐CoV‐2 vaccines do not have significant impacts on the safety and efficacy of biologics (TNF‐α inhibitors or IL‐17A inhibitors) in patients with moderate to severe plaque psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsCOVID-19PsoriasisHumansCOVID-19 VaccinesTumor Necrosis Factor-alphaInterleukin-17Interleukin InhibitorsQuality of LifeSARS-CoV-2Treatment OutcomeVaccines, Inactivated

Stichwörter der Autor:innen

biologicsinactivated SARS-CoV-2 vaccinepsoriasis

Substanzen

COVID-19 VaccinesTumor Necrosis Factor-alphaInterleukin-17Interleukin InhibitorsBiological Productssinovac COVID-19 vaccineVaccines, InactivatedBIBP COVID-19 vaccine

Autor:innen und Institutionen

  • The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'An, Shaanxi, China.
  • Xi'an Jiaotong University Medical School in Department of Nursing, Xi'an, China.

ORCID-Profile: Shuhong Ye

Zitieren

APA

Ye, S., Sun, H., Xu, Z., Xu, B., Wu, N., & Wu, J. (2023). A study of the efficacy and safety of plaque psoriasis treatment by TNF‐α and IL‐17A inhibitor biologics in patients who received the inactivated SARS‐CoV‐2 vaccine. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.938

Vancouver

Ye S, Sun H, Xu Z, Xu B, Wu N, Wu J. A study of the efficacy and safety of plaque psoriasis treatment by TNF‐α and IL‐17A inhibitor biologics in patients who received the inactivated SARS‐CoV‐2 vaccine. Immunity, Inflammation and Disease. 2023. doi:10.1002/iid3.938

BibTeX
@article{Ye2023,
  author = {Ye, Shuhong and Sun, Hong and Xu, Zining and Xu, Bingyang and Wu, Na and Wu, Jiawen},
  title = {A study of the efficacy and safety of plaque psoriasis treatment by TNF‐α and IL‐17A inhibitor biologics in patients who received the inactivated SARS‐CoV‐2 vaccine},
  journal = {Immunity, Inflammation and Disease},
  year = {2023},
  doi = {10.1002/iid3.938}
}
Kostenlos starten →